These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 17587254

  • 1. Once-weekly 22microg subcutaneous IFN-beta-1a in secondary progressive MS: a 3-year follow-up study on brain MRI measurements and serum MMP-9 levels.
    Wu X, Kuusisto H, Dastidar P, Huhtala H, Nikkari ST, Ukkonen M, Höyhtyä M, Elovaara I.
    Acta Neurol Scand; 2007 Jul; 116(1):43-8. PubMed ID: 17587254
    [Abstract] [Full Text] [Related]

  • 2. Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS.
    Wu X, Dastidar P, Kuusisto H, Ukkonen M, Huhtala H, Elovaara I.
    Acta Neurol Scand; 2005 Oct; 112(4):242-7. PubMed ID: 16146494
    [Abstract] [Full Text] [Related]

  • 3. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
    Dubois B, Leary SM, Nelissen I, Opdenakker G, Giovannoni G, Thompson AJ.
    J Neurol; 2003 Sep; 250(9):1037-43. PubMed ID: 14504963
    [Abstract] [Full Text] [Related]

  • 4. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 5. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 26; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
    Arch Neurol; 2008 Feb 26; 65(2):199-204. PubMed ID: 18071030
    [Abstract] [Full Text] [Related]

  • 7. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
    Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, Myhr KM, Sandberg-Wollheim M, Soelberg Sørensen P.
    J Neurol Neurosurg Psychiatry; 2004 May 26; 75(5):706-10. PubMed ID: 15090564
    [Abstract] [Full Text] [Related]

  • 8. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 26; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 9. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis.
    Yushchenko M, Mäder M, Elitok E, Bitsch A, Dressel A, Tumani H, Bogumil T, Kitze B, Poser S, Weber F.
    J Neurol; 2003 Oct 26; 250(10):1224-8. PubMed ID: 14586607
    [Abstract] [Full Text] [Related]

  • 10. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
    Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G, EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group, University of British Columbia MS/MRI Research Group.
    Arch Neurol; 2005 May 26; 62(5):785-92. PubMed ID: 15883267
    [Abstract] [Full Text] [Related]

  • 11. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.
    Patti F, Pappalardo A, Florio C, Politi G, Fiorilla T, Reggio E, Reggio A.
    Acta Neurol Scand; 2006 Apr 26; 113(4):241-7. PubMed ID: 16542163
    [Abstract] [Full Text] [Related]

  • 12. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
    Fernández O, Guerrero M, Mayorga C, Muñoz L, Leán A, Luque G, Hervás M, Fernández V, Capdevila A, de Ramón E.
    J Neurol; 2002 Aug 26; 249(8):1058-62. PubMed ID: 12195454
    [Abstract] [Full Text] [Related]

  • 13. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
    Cocco E, Marchi P, Floris G, Mascia MG, Deriu M, Sirca A, Mamusa E, Lai M, Mura M, Mallarini G, Marrosu MG.
    Funct Neurol; 2006 Aug 26; 21(3):145-9. PubMed ID: 17049133
    [Abstract] [Full Text] [Related]

  • 14. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
    Mult Scler; 2009 Aug 26; 15(8):965-76. PubMed ID: 19465443
    [Abstract] [Full Text] [Related]

  • 15. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L.
    J Neurol Sci; 2004 Jul 15; 222(1-2):13-9. PubMed ID: 15240190
    [Abstract] [Full Text] [Related]

  • 16. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP, Rovaris M, Comi G, Filippi M.
    Neurology; 2009 Nov 10; 73(19):1538-42. PubMed ID: 19794123
    [Abstract] [Full Text] [Related]

  • 17. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
    Murray TJ.
    Curr Med Res Opin; 2004 Jan 10; 20(1):25-30. PubMed ID: 14741068
    [Abstract] [Full Text] [Related]

  • 18. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V.
    Clin Neurol Neurosurg; 2006 Feb 10; 108(2):124-8. PubMed ID: 16412833
    [Abstract] [Full Text] [Related]

  • 19. The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis.
    Motamed MR, Najimi N, Fereshtehnejad SM.
    Clin Neurol Neurosurg; 2007 May 10; 109(4):344-9. PubMed ID: 17300863
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, Gasperini C.
    J Neurol Sci; 2012 Jan 15; 312(1-2):97-101. PubMed ID: 21880336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.